Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOIO: Reduced Dose Intensity of IO in Responding Advanced Cancer Patients
NCT05078047Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Mar 2022
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic cancer (2 arms), sponsored by Unicancer. Primary endpoint: Progression-Free Survival up to 3 years. Started Mar 2022; status: active, not recruiting.
02
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT05078047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078047.